Compare AXGN & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXGN | PHVS |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | N/A | 2021 |
| Metric | AXGN | PHVS |
|---|---|---|
| Price | $33.29 | $26.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | $33.67 | ★ $39.44 |
| AVG Volume (30 Days) | ★ 1.0M | 138.4K |
| Earning Date | 02-24-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $214,709,000.00 | N/A |
| Revenue This Year | $21.98 | N/A |
| Revenue Next Year | $15.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.72 | N/A |
| 52 Week Low | $9.22 | $11.51 |
| 52 Week High | $36.00 | $29.80 |
| Indicator | AXGN | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 49.68 | 51.19 |
| Support Level | $30.98 | $25.69 |
| Resistance Level | $35.65 | $27.59 |
| Average True Range (ATR) | 1.70 | 1.41 |
| MACD | -0.27 | -0.09 |
| Stochastic Oscillator | 43.43 | 49.81 |
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.